Corline Biomedical AB engages in the business of developing a portfolio of drug candidates for use in connection with organ and cell transplantation. The firm is also involved in developing, manufacturing, and marketing heparin-based solutions to improve kidney transplantation, cell therapies, and applications in the evolving field of regenerative medicine. The company was founded in 1991 and is headquartered in Uppsala, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company